{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:53:40Z","timestamp":1791096820034,"version":"4.1.0"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:00:00Z","timestamp":1791072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:00:00Z","timestamp":1791072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Covenant Applied Informatics and Communication Africa Centre of Excellence"},{"DOI":"10.13039\/100004421","name":"World Bank Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004421","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["In Silico Pharmacol."],"DOI":"10.1007\/s40203-026-00762-w","type":"journal-article","created":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:45:21Z","timestamp":1791096321000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring cheminformatics tools to combat prostate cancer: diagnostics, therapeutics, and mechanistic studies"],"prefix":"10.1007","volume":"14","author":[{"given":"Samuel","family":"Igwe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril Osereme","family":"Ehi-Eromosele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inemesit Asukwo","family":"Udofia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwakemi Adekunbi","family":"Oloba-Whenu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,4]]},"reference":[{"issue":"1","key":"762_CR131","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1146\/annurev-pharmtox-121924-042636","volume":"66","author":"A \u00c1lvarez-P\u00e9rez","year":"2026","unstructured":"\u00c1lvarez-P\u00e9rez A, Prieto-Santamar\u00eda L, Casas AI, Loscalzo J, Rodr\u00edguez-Gonz\u00e1lez A (2026) Navigating the computational landscape for drug repurposing. Annu Rev Pharmacol Toxicol 66(1):149\u2013170. https:\/\/doi.org\/10.1146\/annurev-pharmtox-121924-042636","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"762_CR129","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12894-024-01521-9","volume":"24","author":"BO Ajiboye","year":"2024","unstructured":"Ajiboye BO, Fatoki TH, Akinola OG, Ajeigbe KO, Bamisaye AF, Dom\u00ednguez-Mart\u00edn EM, Rijo P, Oyinloye BE (2024) In silico exploration of anti-prostate cancer compounds from differential expressed genes. BMC Urol 24(1):138. https:\/\/doi.org\/10.1186\/s12894-024-01521-9","journal-title":"BMC Urol"},{"issue":"5","key":"762_CR153","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3390\/ph17050551","volume":"17","author":"A Ajmal","year":"2024","unstructured":"Ajmal A, Danial M, Zulfat M, Numan M, Zakir S, Hayat C, Alabbosh KF, Zaki ME, Ali A, Wei D (2024) In silico prediction of new inhibitors for kirsten rat sarcoma g12d cancer drug target using machine learning-based virtual screening, molecular docking, and molecular dynamic simulation approaches. Pharmaceuticals 17(5):551. https:\/\/doi.org\/10.3390\/ph17050551","journal-title":"Pharmaceuticals"},{"issue":"2","key":"762_CR78","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1039\/d2md00285j","volume":"14","author":"BO Al-Najjar","year":"2023","unstructured":"Al-Najjar BO, Abbas MA, Sibai OA, Saqallah FG, Al-Kabariti AY (2023) QSAR, structure-based pharmacophore modelling and biological evaluation of novel platelet ADP receptor (P2Y12) antagonist. RSC Med Chem 14(2):239\u2013246. https:\/\/doi.org\/10.1039\/d2md00285j","journal-title":"RSC Med Chem"},{"issue":"1","key":"762_CR63","doi-asserted-by":"publisher","first-page":"12764","DOI":"10.1038\/s41598-025-97208-8","volume":"15","author":"FM Aldakheel","year":"2025","unstructured":"Aldakheel FM, Alduraywish SA, Dabwan KH (2025) Integrating machine learning driven virtual screening and molecular dynamics simulations to identify potential inhibitors targeting PARP1 against prostate cancer. Sci Rep 15(1):12764. https:\/\/doi.org\/10.1038\/s41598-025-97208-8","journal-title":"Sci Rep"},{"issue":"23","key":"762_CR21","doi-asserted-by":"publisher","first-page":"14232","DOI":"10.1080\/07391102.2023.2179542","volume":"41","author":"KS Andalib","year":"2023","unstructured":"Andalib KS, Rahman MH, Habib A (2023) Bioinformatics and cheminformatics approaches to identify pathways, molecular mechanisms and drug substances related to genetic basis of cervical cancer. J Biomol Struct Dyn 41(23):14232\u201314247. https:\/\/doi.org\/10.1080\/07391102.2023.2179542","journal-title":"J Biomol Struct Dyn"},{"key":"762_CR103","doi-asserted-by":"publisher","DOI":"10.58647\/DRUGARXIV.PR000007.v1","author":"E Anokian","year":"2024","unstructured":"Anokian E, Bernett J, Freeman A, List M, Prieto Santamar\u00eda L, Tanoli Z, Bonnin S (2024) Machine Learning and Artificial Intelligence in drug repurposing\u2013challenges and perspectives. DrugRxiv. https:\/\/doi.org\/10.58647\/DRUGARXIV.PR000007.v1","journal-title":"DrugRxiv"},{"issue":"9","key":"762_CR109","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/mc.23565","volume":"62","author":"IM Atawia","year":"2023","unstructured":"Atawia IM, Kushwaha PP, Verma S, Lin S, Shankar E, Abdel-Gawad O, Gupta S (2023) Inhibition of Wnt\/\u03b2\u2010catenin pathway overcomes therapeutic resistance to abiraterone in castration\u2010resistant prostate cancer. Mol Carcinog 62(9):1312\u20131324. https:\/\/doi.org\/10.1002\/mc.23565","journal-title":"Mol Carcinog"},{"issue":"12","key":"762_CR108","doi-asserted-by":"publisher","first-page":"e202400905","DOI":"10.1002\/cbdv.202400905","volume":"21","author":"H Atmaca","year":"2024","unstructured":"Atmaca H, \u00c7amli Pulat \u00c7, Ilhan S, Kalyoncu F (2024) Hericium erinaceus extract induces apoptosis via PI3K\/AKT and RAS\/MAPK signaling pathways in prostate cancer cells. Chem Biodivers 21(12):e202400905. https:\/\/doi.org\/10.1002\/cbdv.202400905","journal-title":"Chem Biodivers"},{"issue":"1","key":"762_CR90","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40200-022-01109-w","volume":"22","author":"PK Ayd\u0131n","year":"2023","unstructured":"Ayd\u0131n PK, Turky\u0131lmaz IB, Gul IB, Bulan OK, Yanardag R (2023) Drug repurposing: Metformin\u2019s effect against liver tissue damage in diabetes and prostate cancer model. J Diabetes Metab Disord 22(1):225\u2013236. https:\/\/doi.org\/10.1007\/s40200-022-01109-w","journal-title":"J Diabetes Metab Disord"},{"key":"762_CR123","doi-asserted-by":"publisher","unstructured":"Badar MS, Shamsi S, Ahmed J, Alam MA (2022) Molecular dynamics simulations: concept, methods, and applications. In: Transdisciplinarity (pp. 131\u2013151). Cham: Springer International Publishing. https:\/\/doi.org\/10.1007\/978-3-030-94651-7_7","DOI":"10.1007\/978-3-030-94651-7_7"},{"issue":"1","key":"762_CR86","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/medsci10010015","volume":"10","author":"HF Bahmad","year":"2022","unstructured":"Bahmad HF, Demus T, Moubarak MM, Daher D, Alvarez Moreno JC, Polit F, Lopez O, Merhe A, Abou-Kheir W, Nieder AM, Poppiti R (2022) Overcoming drug resistance in advanced prostate cancer by drug repurposing. Med Sci 10(1):15. https:\/\/doi.org\/10.3390\/medsci10010015","journal-title":"Med Sci"},{"issue":"9","key":"762_CR65","doi-asserted-by":"publisher","first-page":"104130","DOI":"10.1016\/j.drudis.2024.104130","volume":"29","author":"JP Batista-Silva","year":"2024","unstructured":"Batista-Silva JP, Gomes D, Sousa SF, Sousa \u00c2, Passarinha LA (2024) Advances in structure-based drug design targeting membrane protein markers in prostate cancer. Drug Discov Today 29(9):104130. https:\/\/doi.org\/10.1016\/j.drudis.2024.104130","journal-title":"Drug Discov Today"},{"issue":"3","key":"762_CR38","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3390\/ph17030351","volume":"17","author":"A Bernal","year":"2024","unstructured":"Bernal A, Bechler AJ, Mohan K, Rizzino A, Mathew G (2024) The current therapeutic landscape for metastatic prostate cancer. Pharmaceuticals 17(3):351. https:\/\/doi.org\/10.3390\/ph17030351","journal-title":"Pharmaceuticals"},{"issue":"3","key":"762_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"Cancer J Clin"},{"issue":"4","key":"762_CR152","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1007\/s11030-025-11184-9","volume":"29","author":"K Cao","year":"2025","unstructured":"Cao K, Wang R, Wu S, Ou D, Li R, Li L, Liu X (2025) Targeting Poly (ADP-ribose) polymerase-1 (PARP-1) for DNA repair mechanism through QSAR-based virtual screening and MD simulation. Mol Diversity 29(4):3517\u20133535. https:\/\/doi.org\/10.1007\/s11030-025-11184-9","journal-title":"Mol Diversity"},{"issue":"1","key":"762_CR39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/03915603211042335","volume":"89","author":"F Cellini","year":"2022","unstructured":"Cellini F, Tagliaferri L, Frascino V, Alitto AR, Fionda B, Boldrini L, Romano A, Cas\u00e0 C, Catucci F, Mattiucci GC, Valentini V (2022) Radiation therapy for prostate cancer: what\u2019s the best in 2021. Urol J 89(1):5\u201315. https:\/\/doi.org\/10.1177\/03915603211042335","journal-title":"Urol J"},{"issue":"15","key":"762_CR133","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.3390\/cancers15153839","volume":"15","author":"A Chaddad","year":"2023","unstructured":"Chaddad A, Tan G, Liang X, Hassan L, Rathore S, Desrosiers C, Katib Y, Niazi T (2023) Advancements in MRI-based radiomics and artificial intelligence for prostate cancer: a comprehensive review and future prospects. Cancers 15(15):3839. https:\/\/doi.org\/10.3390\/cancers15153839","journal-title":"Cancers"},{"issue":"4","key":"762_CR155","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1080\/07391102.2023.2294168","volume":"43","author":"Y Chang","year":"2025","unstructured":"Chang Y, Zhou H, Ren Y, Zhang J, Sun L, Du M, Zhao J, Chu H, Zhao Y (2025) Identifying multi-target drugs for prostate cancer using machine learning-assisted transcriptomic analysis. J Biomol Struct Dyn 43(4):2109\u20132119. https:\/\/doi.org\/10.1080\/07391102.2023.2294168","journal-title":"J Biomol Struct Dyn"},{"issue":"2","key":"762_CR53","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1148\/radiol.2021204459","volume":"302","author":"A Chatterjee","year":"2022","unstructured":"Chatterjee A, Mercado C, Bourne RM, Yousuf A, Hess B, Antic T, Eggener S, Oto A, Karczmar GS (2022) Validation of prostate tissue composition by using hybrid multidimensional MRI: correlation with histologic findings. Radiology 302(2):368\u2013377. https:\/\/doi.org\/10.1148\/radiol.2021204459","journal-title":"Radiology"},{"key":"762_CR144","doi-asserted-by":"publisher","unstructured":"Chatterjee S, Kundu S, Sarkar N (2026) Leveraging artificial intelligence for drug development and drug discovery. In: Bioinformatics, AI, and Machine Learning in Microbial Drug Development (pp. 233\u2013262). Academic Press. https:\/\/doi.org\/10.1016\/B978-0-443-33032-2.00018-6","DOI":"10.1016\/B978-0-443-33032-2.00018-6"},{"issue":"8","key":"762_CR81","doi-asserted-by":"publisher","first-page":"12048","DOI":"10.3390\/molecules190812048","volume":"19","author":"H Chen","year":"2014","unstructured":"Chen H, Liang X, Xu F, Xu B, He X, Huang B, Yuan M (2014) Synthesis and cytotoxic activity evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines. Molecules 19(8):12048\u201312064. https:\/\/doi.org\/10.3390\/molecules190812048","journal-title":"Molecules"},{"key":"762_CR57","doi-asserted-by":"publisher","unstructured":"Chikwambi Z, Hidjo M, Chikondowa P, Jayeoba G, Aketch V, Afolabi L, Awe OI, Enoma D (2023) Multi-omics data integration approach identifies potential biomarkers for Prostate cancer. BioRxiv. https:\/\/doi.org\/10.1101\/2023.01.26.522643","DOI":"10.1101\/2023.01.26.522643"},{"issue":"1","key":"762_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12957-025-03733-1","volume":"23","author":"F Chu","year":"2025","unstructured":"Chu F, Chen L, Guan Q, Chen Z, Ji Q, Ma Y, Ji J, Sun M, Huang T, Song H, Zhou H (2025) Global burden of prostate cancer: age-period-cohort analysis from 1990 to 2021 and projections until 2040. World J Surg Oncol 23(1):98. https:\/\/doi.org\/10.1186\/s12957-025-03733-1","journal-title":"World J Surg Oncol"},{"issue":"15","key":"762_CR106","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/ajhp\/zxac105","volume":"79","author":"C Chung","year":"2022","unstructured":"Chung C, Abboud K (2022) Targeting the androgen receptor signaling pathway in advanced prostate cancer. Am J Health-System Pharm 79(15):1224\u20131235. https:\/\/doi.org\/10.1093\/ajhp\/zxac105","journal-title":"Am J Health-System Pharm"},{"issue":"3","key":"762_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4111\/icu.20240456","volume":"66","author":"Y Chung","year":"2025","unstructured":"Chung Y, Hong SK (2025) Evaluating prostate cancer diagnostic methods: the role and relevance of digital rectal examination in modern era. Invest Clin Urol 66(3):181. https:\/\/doi.org\/10.4111\/icu.20240456","journal-title":"Invest Clin Urol"},{"issue":"10","key":"762_CR52","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1007\/s00261-024-04423-4","volume":"49","author":"ET Correia","year":"2024","unstructured":"Correia ET, Baydoun A, Li Q, Costa DN, Bittencourt LK (2024) Emerging and anticipated innovations in prostate cancer MRI and their impact on patient care. Abdom Radiol 49(10):3696\u20133710. https:\/\/doi.org\/10.1007\/s00261-024-04423-4","journal-title":"Abdom Radiol"},{"issue":"6","key":"762_CR18","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3390\/ph18060888","volume":"18","author":"NS Costa","year":"2025","unstructured":"Costa NS, Lima LR, Cruz JN, Santos IV, Silva RC, Maciel AA, Barros ES, Andrade ML, Ramos RS, Kimani NM, Arag\u00f3n-Muriel A (2025) Identification of inhibitors with potential Anti-Prostate cancer activity: a chemoinformatics approach. Pharmaceuticals 18(6):888. https:\/\/doi.org\/10.3390\/ph18060888","journal-title":"Pharmaceuticals"},{"issue":"13","key":"762_CR29","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.3390\/cancers14133272","volume":"14","author":"F Crocetto","year":"2022","unstructured":"Crocetto F, Russo G, Di Zazzo E, Pisapia P, Mirto BF, Palmieri A, Pepe F, Bellevicine C, Russo A, La Civita E, Terracciano D (2022) Liquid biopsy in prostate cancer management: current challenges and future perspectives. Cancers 14(13):3272. https:\/\/www.mdpi.com\/2072-6694\/14\/13\/3272","journal-title":"Cancers"},{"key":"762_CR79","doi-asserted-by":"publisher","first-page":"108714","DOI":"10.1016\/j.bioorg.2025.108714","volume":"163","author":"Q Cui","year":"2025","unstructured":"Cui Q, Huang C, Zheng X, Dong Z, Liu JY, Zhang JT (2025) Design, synthesis, and evaluation of quinoxaline-based survivin inhibitors for castration-resistant prostate cancer. Bioorg Chem 163:108714. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108714","journal-title":"Bioorg Chem"},{"issue":"10","key":"762_CR13","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1007\/s12094-024-03508-2","volume":"26","author":"V Dahiya","year":"2024","unstructured":"Dahiya V, Hans S, Kumari R, Bagchi G (2024) Prostate cancer biomarkers: from early diagnosis to precision treatment. Clin Transl Oncol 26(10):2444\u20132456. https:\/\/doi.org\/10.1007\/s12094-024-03508-2","journal-title":"Clin Transl Oncol"},{"issue":"6","key":"762_CR73","doi-asserted-by":"publisher","first-page":"e70136","DOI":"10.1111\/cbdd.70136","volume":"105","author":"T Diao","year":"2025","unstructured":"Diao T, Feng C, Liu S, Song JL, Zhu KK, Jiang CS, Fu Q (2025) Identification of a Selective Cell-Active Inhibitor of Protein Arginine Methyltransferase 5 (PRMT5) for the Treatment of Prostate Cancer by Structure\u2010Based Virtual Screening. Chem Biol Drug Des 105(6):e70136. https:\/\/doi.org\/10.1111\/cbdd.70136","journal-title":"Chem Biol Drug Des"},{"issue":"1","key":"762_CR47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41391-023-00708-9","volume":"27","author":"F Ditonno","year":"2024","unstructured":"Ditonno F, Franco A, Manfredi C, Veccia A, Valerio M, Bukavina L, Zukowski LB, Vourganti S, Stenzl A, Andriole GL, Antonelli A (2024) Novel non-MRI imaging techniques for primary diagnosis of prostate cancer: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET\/CT. Prostate Cancer Prostatic Dis 27(1):29\u201336. https:\/\/doi.org\/10.1038\/s41391-023-00708-9","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"762_CR71","doi-asserted-by":"publisher","DOI":"10.1007\/s11696-026-04704-w","author":"J Dong","year":"2026","unstructured":"Dong J, Hao X (2026) Pharmacophore-based virtual screening, molecular docking, and molecular dynamics simulation for the identification of novel BRD4 (BD1) inhibitors. Chem Papers. https:\/\/doi.org\/10.1007\/s11696-026-04704-w","journal-title":"Chem Papers"},{"issue":"2","key":"762_CR31","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1177\/08953996241304988","volume":"33","author":"Y Dong","year":"2025","unstructured":"Dong Y, Wang P, Geng H, Liu Y, Wang E (2025) Ultrasound and advanced imaging techniques in prostate cancer diagnosis: a comparative study of mpMRI, TRUS and PET\/CT. J X-Ray Sci Technol 33(2):436\u2013447. https:\/\/doi.org\/10.1177\/08953996241304988","journal-title":"J X-Ray Sci Technol"},{"issue":"4","key":"762_CR49","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s10334-022-01031-5","volume":"35","author":"DK Dwivedi","year":"2022","unstructured":"Dwivedi DK, Jagannathan NR (2022) Emerging MR methods for improved diagnosis of prostate cancer by multiparametric MRI. Magn Reson Mater Phys Biol Med 35(4):587\u2013608. https:\/\/doi.org\/10.1007\/s10334-022-01031-5","journal-title":"Magn Reson Mater Phys Biol Med"},{"key":"762_CR145","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.3332\/ecancer.2025.1953","volume":"19","author":"ZH Ejaz","year":"2025","unstructured":"Ejaz ZH, Shaikh RH, Fatimi AS, Khan SR (2025) Unlocking artificial intelligence, machine learning, and deep learning to combat therapeutic resistance in metastatic castration-resistant prostate cancer: a comprehensive review. ecancermedicalscience 19:1953. https:\/\/doi.org\/10.3332\/ecancer.2025.1953","journal-title":"ecancermedicalscience"},{"issue":"7880","key":"762_CR150","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41586-021-03922-4","volume":"598","author":"HA Elmarakeby","year":"2021","unstructured":"Elmarakeby HA, Hwang J, Arafeh R, Crowdis J, Gang S, Liu D, AlDubayan SH, Salari K, Kregel S, Richter C, Arnoff TE (2021) Biologically informed deep neural network for prostate cancer discovery. Nature 598(7880):348\u2013352. https:\/\/doi.org\/10.1038\/s41586-021-03922-4","journal-title":"Nature"},{"issue":"3","key":"762_CR70","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1007\/s11030-025-11359-4","volume":"30","author":"Z Fan","year":"2026","unstructured":"Fan Z, Hao X, Chen W, Xu Z, Wang Q, Li M, Zhang H, Ren C, Chen Y, Lin J, Liu X (2026) Virtual screening and experimental validation of small-molecule compounds targeting AR in prostate cancer. Mol Divers 30(3):4285\u20134299. https:\/\/doi.org\/10.1007\/s11030-025-11359-4","journal-title":"Mol Divers"},{"key":"762_CR128","doi-asserted-by":"publisher","first-page":"116925","DOI":"10.1016\/j.ejmech.2024.116925","volume":"280","author":"I Fatima","year":"2024","unstructured":"Fatima I, Rehman A, Ding Y, Meng Y, Rehman HU, Warraich DA, Wang Z, Feng L, Liao M (2024) Breakthroughs in AI and multi-omics for cancer drug discovery: a review. Eur J Med Chem 280:116925. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116925","journal-title":"Eur J Med Chem"},{"issue":"8","key":"762_CR88","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.3390\/cancers14082043","volume":"14","author":"A Federico","year":"2022","unstructured":"Federico A, Fratello M, Scala G, M\u00f6bus L, Pavel A, Del Giudice G, Ceccarelli M, Costa V, Ciccodicola A, Fortino V, Serra A (2022) Integrated network pharmacology approach for drug combination discovery: a multi-cancer case study. Cancers 14(8):2043. https:\/\/doi.org\/10.3390\/cancers14082043","journal-title":"Cancers"},{"issue":"1","key":"762_CR83","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1038\/s41467-024-49360-4","volume":"15","author":"S Figarol","year":"2024","unstructured":"Figarol S, Delahaye C, Gence R, Doussine A, Cerapio JP, Brachais M, Tardy C, B\u00e9ry N, Asslan R, Colinge J, Villemin JP (2024) Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies. Nat Commun 15(1):5345. https:\/\/doi.org\/10.1038\/s41467-024-49360-4","journal-title":"Nat Commun"},{"key":"762_CR26","doi-asserted-by":"publisher","first-page":"106588","DOI":"10.1016\/j.jsbmb.2024.106588","volume":"243","author":"L Galey","year":"2024","unstructured":"Galey L, Olanrewaju A, Nabi H, Paquette JS, Pouliot F, Audet-Walsh E (2024) PSA, an outdated biomarker for prostate cancer: in search of a more specific biomarker, citrate takes the spotlight. J Steroid Biochem Mol Biol 243:106588. https:\/\/doi.org\/10.1016\/j.jsbmb.2024.106588","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"1","key":"762_CR62","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12935-022-02691-y","volume":"22","author":"N Gholami","year":"2022","unstructured":"Gholami N, Haghparast A, Alipourfard I, Nazari M (2022) Prostate cancer in omics era. Cancer Cell Int 22(1):274. https:\/\/doi.org\/10.1186\/s12935-022-02691-y","journal-title":"Cancer Cell Int"},{"issue":"5","key":"762_CR66","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3390\/ph15050646","volume":"15","author":"D Giordano","year":"2022","unstructured":"Giordano D, Biancaniello C, Argenio MA, Facchiano A (2022) Drug design by pharmacophore and virtual screening approach. Pharmaceuticals 15(5):646. https:\/\/doi.org\/10.3390\/ph15050646","journal-title":"Pharmaceuticals"},{"issue":"3","key":"762_CR60","doi-asserted-by":"publisher","first-page":"596","DOI":"10.3390\/cancers14030596","volume":"14","author":"N Gomez-Cebrian","year":"2022","unstructured":"Gomez-Cebrian N, Poveda JL, Pineda-Lucena A, Puchades-Carrasco L (2022) Metabolic phenotyping in prostate cancer using multi-omics approaches. Cancers 14(3):596. https:\/\/doi.org\/10.3390\/cancers14030596","journal-title":"Cancers"},{"issue":"6","key":"762_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/13543776.2021.1878145","volume":"31","author":"H Ha","year":"2021","unstructured":"Ha H, Kwon H, Lim T, Jang J, Park SK, Byun Y (2021) Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer\u2013a review of patent literature. Expert Opin Ther Pat 31(6):525\u2013547. https:\/\/doi.org\/10.1080\/13543776.2021.1878145","journal-title":"Expert Opin Ther Pat"},{"key":"762_CR48","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.euros.2022.04.001","volume":"40","author":"MJ Hagens","year":"2022","unstructured":"Hagens MJ, Salamanca MF, Padhani AR, van Leeuwen PJ, van der Poel HG, Schoots IG (2022) Diagnostic performance of a magnetic resonance imaging-directed targeted plus regional biopsy approach in prostate cancer diagnosis: a systematic review and meta-analysis. Eur Urol open Sci 40:95\u2013103. https:\/\/doi.org\/10.1016\/j.euros.2022.04.001","journal-title":"Eur Urol open Sci"},{"issue":"4","key":"762_CR146","doi-asserted-by":"publisher","first-page":"e222276","DOI":"10.1148\/radiol.222276","volume":"307","author":"CA Hamm","year":"2023","unstructured":"Hamm CA, Baumg\u00e4rtner GL, Biessmann F, Beetz NL, Hartenstein A, Savic LJ, Frob\u00f6se K, Dr\u00e4ger F, Schallenberg S, Rudolph M, Baur AD (2023) Interactive explainable deep learning model informs prostate cancer diagnosis at MRI. Radiology 307(4):e222276. https:\/\/doi.org\/10.1148\/radiol.222276","journal-title":"Radiology"},{"issue":"1","key":"762_CR104","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","volume":"7","author":"Y He","year":"2022","unstructured":"He Y, Xu W, Xiao YT, Huang H, Gu D, Ren S (2022) Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduct Target Therapy 7(1):198. https:\/\/doi.org\/10.1038\/s41392-022-01042-7","journal-title":"Signal Transduct Target Therapy"},{"issue":"1","key":"762_CR34","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/s12885-023-10842-1","volume":"23","author":"BL Heesterman","year":"2023","unstructured":"Heesterman BL, Aben KK, de Jong IJ, Pos FJ, van der Hel OL (2023) Radical prostatectomy versus external beam radiotherapy with androgen deprivation therapy for high-risk prostate cancer: a systematic review. BMC Cancer 23(1):398. https:\/\/doi.org\/10.1186\/s12885-023-10842-1","journal-title":"BMC Cancer"},{"issue":"3","key":"762_CR41","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41391-023-00785-w","volume":"27","author":"DE Hinojosa-Gonzalez","year":"2024","unstructured":"Hinojosa-Gonzalez DE, Zafar A, Saffati G, Kronstedt S, Zlatev DV, Khera M (2024) Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 27(3):507\u2013519. https:\/\/doi.org\/10.1038\/s41391-023-00785-w","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"17","key":"762_CR55","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.3390\/diagnostics14171871","volume":"14","author":"A Horasan","year":"2024","unstructured":"Horasan A, G\u00fcne\u015f A (2024) Advancing prostate cancer diagnosis: a deep learning approach for enhanced detection in MRI images. Diagnostics 14(17):1871. https:\/\/doi.org\/10.3390\/diagnostics14171871","journal-title":"Diagnostics"},{"issue":"2","key":"762_CR93","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/ph15020131","volume":"15","author":"YC Hou","year":"2022","unstructured":"Hou YC, Shao YH (2022) The effects of statins on prostate cancer patients receiving androgen deprivation therapy or definitive therapy: a systematic review and meta-analysis. Pharmaceuticals 15(2):131. https:\/\/doi.org\/10.3390\/ph15020131","journal-title":"Pharmaceuticals"},{"key":"762_CR122","doi-asserted-by":"publisher","first-page":"134824","DOI":"10.1016\/j.foodchem.2022.134824","volume":"405","author":"X Hu","year":"2023","unstructured":"Hu X, Zeng Z, Zhang J, Wu D, Li H, Geng F (2023) Molecular dynamics simulation of the interaction of food proteins with small molecules. Food Chem 405:134824. https:\/\/doi.org\/10.1016\/j.foodchem.2022.134824","journal-title":"Food Chem"},{"issue":"1","key":"762_CR67","doi-asserted-by":"publisher","first-page":"29404","DOI":"10.1038\/s41598-025-15038-0","volume":"15","author":"X Huang","year":"2025","unstructured":"Huang X, Hu J (2025) In Silico discovery of novel androgen receptor inhibitors for prostate cancer therapy using virtual screening, molecular docking, and molecular dynamics simulations. Sci Rep 15(1):29404. https:\/\/doi.org\/10.1038\/s41598-025-15038-0","journal-title":"Sci Rep"},{"key":"762_CR116","doi-asserted-by":"publisher","first-page":"1654757","DOI":"10.3389\/fphar.2025.1654757","volume":"16","author":"Y Huang","year":"2025","unstructured":"Huang Y, Bai J, Ran B, Li J, Chen B, Chen Z, Chen J, Wang Y, Li J, Dong Q, Wei Q (2025) Cepharanthine may inhibit the proliferation of prostate cells by blocking the EGFR\/PI3K\/AKT signaling pathway: comprehensive network analysis, molecular docking, and experimental evaluation. Front Pharmacol 16:1654757. https:\/\/doi.org\/10.3389\/fphar.2025.1654757","journal-title":"Front Pharmacol"},{"issue":"2","key":"762_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3892\/ijo.2025.5828","volume":"68","author":"Y Huang","year":"2025","unstructured":"Huang Y, Mao J, Li X (2025) Emerging biomarkers in prostate cancer diagnosis and treatment: insights into genetic, RNA and metabolic markers. Int J Oncol 68(2):15. https:\/\/doi.org\/10.3892\/ijo.2025.5828","journal-title":"Int J Oncol"},{"issue":"1","key":"762_CR87","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s40360-025-00983-3","volume":"26","author":"LM Irham","year":"2025","unstructured":"Irham LM, Adikusuma W, Afief AR, Khairi S, Chong R, Mufidah S, Satria RD, Mugiyanto E, Darmawi D, Amukti DP, Wirsahada BC (2025) Integrative genomic and bioinformatic prioritization of drug repurposing candidates for prostate cancer. BMC Pharmacol Toxicol 26(1):145. https:\/\/doi.org\/10.1186\/s40360-025-00983-3","journal-title":"BMC Pharmacol Toxicol"},{"issue":"3","key":"762_CR137","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/pharmacy14030085","volume":"14","author":"A Ivanov","year":"2026","unstructured":"Ivanov A, Ruseva V, Hababa-Ivanova I, Getova-Kolarova V, Lebanova H, Getov I (2026) From laboratory to patient access: a scoping review of the multi-dimensional challenges in drug repurposing. Pharmacy 14(3):85. https:\/\/doi.org\/10.3390\/pharmacy14030085","journal-title":"Pharmacy"},{"issue":"10437","key":"762_CR8","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J, Feng F, Gillessen S, Ali SA, Trujillo B, Al-Lazikani B, Attard G, Bray F, Comp\u00e9rat E (2024) The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet 403(10437):1683\u20131722. https:\/\/doi.org\/10.1016\/S0140-6736(24)00651-2","journal-title":"Lancet"},{"issue":"11","key":"762_CR51","doi-asserted-by":"publisher","first-page":"6814","DOI":"10.3390\/curroncol31110503","volume":"31","author":"LJ Jensen","year":"2024","unstructured":"Jensen LJ, Kim D, Elgeti T, Steffen IG, Schaafs LA, Haas M, Kurz LJ, Hamm B, Nagel SN (2024) Detecting clinically significant prostate cancer in PI-RADS 3 lesions using T2w-derived radiomics feature maps in 3T prostate MRI. Curr Oncol 31(11):6814\u20136828. https:\/\/doi.org\/10.3390\/curroncol31110503","journal-title":"Curr Oncol"},{"issue":"1","key":"762_CR16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12935-026-04236-z","volume":"26","author":"H Kalarestaghi","year":"2026","unstructured":"Kalarestaghi H, Amani N, Shoorei H (2026) Regulatory roles of microRNAs in signaling pathways and their biomarker potential in prostate cancer. Cancer Cell Int 26(1):156. https:\/\/doi.org\/10.1186\/s12935-026-04236-z","journal-title":"Cancer Cell Int"},{"issue":"1","key":"762_CR112","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s40203-023-00162-4","volume":"11","author":"F Kalungi","year":"2023","unstructured":"Kalungi F, Nsubuga A, Anywar G (2023) Network analysis and molecular docking studies of quercetin as a potential treatment for prostate cancer. Silico Pharmacol 11(1):24. https:\/\/doi.org\/10.1007\/s40203-023-00162-4","journal-title":"Silico Pharmacol"},{"issue":"3","key":"762_CR100","doi-asserted-by":"publisher","first-page":"439","DOI":"10.5009\/gnl250294","volume":"20","author":"J Kang","year":"2025","unstructured":"Kang J, Kim DK, Seo Y, Yu J, Lee HH, Park J, Park JJ, Cheon JH, Park SJ, Kim TI (2025) Dose-response relationship of niclosamide and metformin combination in ApcMin\/+ Mice: an integrated in vivo and pharmacokinetic modeling study. Gut Liver 20(3):439. https:\/\/doi.org\/10.5009\/gnl250294","journal-title":"Gut Liver"},{"issue":"13","key":"762_CR11","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.3390\/cancers17132137","volume":"17","author":"E Kania","year":"2025","unstructured":"Kania E, Janica M, Nesterowicz M, Modzelewski W, Cybulski M, Janica J (2025) Advances and challenges in prostate cancer diagnosis: a comprehensive review. Cancers 17(13):2137. https:\/\/doi.org\/10.3390\/cancers17132137","journal-title":"Cancers"},{"issue":"2","key":"762_CR147","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4236\/jilsa.2026.182006","volume":"18","author":"AE Karrar","year":"2026","unstructured":"Karrar AE, Explainable AI (2026) Enhancing clinician trust and accuracy in prostate cancer diagnosis. J Intell Learn Syst Appl 18(2):91\u2013104. https:\/\/doi.org\/10.4236\/jilsa.2026.182006","journal-title":"J Intell Learn Syst Appl"},{"key":"762_CR126","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.ijbiomac.2022.07.058","volume":"218","author":"A Khan","year":"2022","unstructured":"Khan A, Mao Y, Tahreem S, Wei DQ, Wang Y (2022) Structural and molecular insights into the mechanism of resistance to enzalutamide by the clinical mutants in androgen receptor (AR) in castration-resistant prostate cancer (CRPC) patients. Int J Biol Macromol 218:856\u2013865. https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.07.058","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"762_CR69","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12906-023-04269-1","volume":"24","author":"H Khan","year":"2024","unstructured":"Khan H, Azad I, Arif Z, Parveen S, Kumar S, Rais J, Ansari JA, Nasibullah M, Kumar S, Arshad M (2024) Structure-based docking and biological evaluation towards exploring potential anti-cancerous and apoptotic activity of 6-Gingerol against human prostate carcinoma cells. BMC Complement Med Ther 24(1):8. https:\/\/doi.org\/10.1186\/s12906-023-04269-1","journal-title":"BMC Complement Med Ther"},{"key":"762_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.20517\/cdr.2024.173","volume":"8","author":"A Khorasanchi","year":"2025","unstructured":"Khorasanchi A, Hong F, Yang Y, Singer EA, Wang P, Li M, Zheng L, Monk P, Mortazavi A, Meng L (2025) Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches. Cancer Drug Resist 8:9. https:\/\/doi.org\/10.20517\/cdr.2024.173","journal-title":"Cancer Drug Resist"},{"issue":"13","key":"762_CR143","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1158\/0008-5472.CAN-24-3630","volume":"85","author":"P Khosravi","year":"2025","unstructured":"Khosravi P, Fuchs TJ, Ho DJ (2025) Artificial intelligence\u2013driven cancer diagnostics: enhancing radiology and pathology through reproducibility, explainability, and multimodality. Cancer Res 85(13):2356\u20132367. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-3630","journal-title":"Cancer Res"},{"issue":"4","key":"762_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.18231\/j.ijcbr.2024.037","volume":"11","author":"P Kiran","year":"2025","unstructured":"Kiran P, Krishna S, Rani S (2025) Comparing the effectiveness of digital rectal examination, prostate specific antigen, and TRUS guided prostate biopsy, in the detection of prostate cancer. Int J 11(4):248\u2013253. https:\/\/doi.org\/10.18231\/j.ijcbr.2024.037","journal-title":"Int J"},{"issue":"6","key":"762_CR7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3322\/caac.70028","volume":"75","author":"TB Kratzer","year":"2025","unstructured":"Kratzer TB, Mazzitelli N, Star J, Dahut WL, Jemal A, Siegel RL (2025) Prostate cancer statistics, 2025. CA A Cancer J Clin 75(6):485\u2013497. https:\/\/doi.org\/10.3322\/caac.70028","journal-title":"CA A Cancer J Clin"},{"issue":"5","key":"762_CR44","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/iub.2665","volume":"75","author":"W Krause","year":"2023","unstructured":"Krause W (2023) Resistance to prostate cancer treatments. IUBMB Life 75(5):390\u2013410. https:\/\/doi.org\/10.1002\/iub.2665","journal-title":"IUBMB Life"},{"issue":"2","key":"762_CR130","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1134\/S1068162023020139","volume":"49","author":"VS Kulkarni","year":"2023","unstructured":"Kulkarni VS, Alagarsamy V, Solomon VR, Jose PA, Murugesan S (2023) Drug repurposing: an effective tool in modern drug discovery. Russ J Bioorg Chem 49(2):157\u2013166. https:\/\/doi.org\/10.1134\/S1068162023020139","journal-title":"Russ J Bioorg Chem"},{"issue":"20","key":"762_CR10","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.3390\/cancers15205047","volume":"15","author":"TK Le","year":"2023","unstructured":"Le TK, Duong QH, Baylot V, Fargette C, Baboudjian M, Colleaux L, Ta\u00efeb D, Rocchi P (2023) Castration-resistant prostate cancer: from uncovered resistance mechanisms to current treatments. Cancers 15(20):5047. https:\/\/doi.org\/10.3390\/cancers15205047","journal-title":"Cancers"},{"issue":"5","key":"762_CR135","doi-asserted-by":"publisher","first-page":"bbaf454","DOI":"10.1093\/bib\/bbaf454","volume":"26","author":"J Lee","year":"2025","unstructured":"Lee J, Hao Nguyen C, Mamitsuka H (2025) Beyond rigid docking: deep learning approaches for fully flexible protein\u2013ligand interactions. Brief Bioinform 26(5):bbaf454. https:\/\/doi.org\/10.1093\/bib\/bbaf454","journal-title":"Brief Bioinform"},{"key":"762_CR148","doi-asserted-by":"publisher","first-page":"810995","DOI":"10.3389\/fmed.2021.810995","volume":"8","author":"D Li","year":"2022","unstructured":"Li D, Han X, Gao J, Zhang Q, Yang H, Liao S, Guo H, Zhang B (2022) Deep learning in prostate cancer diagnosis using multiparametric magnetic resonance imaging with whole-mount histopathology referenced delineations. Front Med 8:810995. https:\/\/doi.org\/10.3389\/fmed.2021.810995","journal-title":"Front Med"},{"issue":"4","key":"762_CR23","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.ultrasmedbio.2024.01.003","volume":"50","author":"J Li","year":"2024","unstructured":"Li J, Zhu C, Yang S, Mao Z, Lin S, Huang H, Xu S (2024) Non-invasive diagnosis of prostate cancer and high-grade prostate cancer using multiparametric ultrasonography and serological examination. Ultrasound Med Biol 50(4):600\u2013609. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2024.01.003","journal-title":"Ultrasound Med Biol"},{"issue":"12","key":"762_CR110","doi-asserted-by":"publisher","first-page":"e33103","DOI":"10.1016\/j.heliyon.2024.e33103","volume":"10","author":"J Li","year":"2024","unstructured":"Li J, Wang X, Xue L, He Q (2024) Exploring the therapeutic mechanism of curcumin in prostate cancer using network pharmacology and molecular docking. Heliyon 10(12):e33103. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33103","journal-title":"Heliyon"},{"issue":"10","key":"762_CR76","doi-asserted-by":"publisher","first-page":"e","DOI":"10.21577\/0103-5053.20240112","volume":"35","author":"AG Lima","year":"2024","unstructured":"Lima AG, Penteado AB, Jesus JG, Paula VJ, Ferraz WR, Trossini GH (2024) Structure-based virtual screening: successes and pitfalls. J Braz Chem Soc 35(10):e\u201320240112. https:\/\/doi.org\/10.21577\/0103-5053.20240112","journal-title":"J Braz Chem Soc"},{"issue":"1","key":"762_CR132","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12967-020-02281-4","volume":"18","author":"Y Lin","year":"2020","unstructured":"Lin Y, Zhao X, Miao Z, Ling Z, Wei X, Pu J, Hou J, Shen B (2020) Data-driven translational prostate cancer research: from biomarker discovery to clinical decision. J Translational Med 18(1):119. https:\/\/doi.org\/10.1186\/s12967-020-02281-4","journal-title":"J Translational Med"},{"issue":"12","key":"762_CR96","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1158\/1078-0432.CCR-13-3296","volume":"20","author":"C Liu","year":"2014","unstructured":"Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC (2014) Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res 20(12):3198\u20133210. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3296","journal-title":"Clin Cancer Res"},{"key":"762_CR117","doi-asserted-by":"publisher","first-page":"117994","DOI":"10.1016\/j.jep.2024.117994","volume":"327","author":"BJ Liu","year":"2024","unstructured":"Liu BJ, Guan YY, Qiao LX, Zhang JM, Li AJ, Yang PX, Gao YX, Chen DX, Wang CX, Wu J (2024) The mechanism and experimental verification of Ixeris sonchifolia promoting apoptosis of hepatocellular carcinoma based on network pharmacology: Ixeris sonchifolia induces hepatocellular carcinoma apoptosis via the PI3K\/AKT pathway. J Ethnopharmacol 327:117994. https:\/\/doi.org\/10.1016\/j.jep.2024.117994","journal-title":"J Ethnopharmacol"},{"issue":"20","key":"762_CR125","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.1021\/acs.jpcb.5c02125","volume":"129","author":"S Liu","year":"2025","unstructured":"Liu S, Sun C, Geng J, Wei L, Su R (2025) Investigating the interaction mechanism of CAT-BT-Br and key residue mutations for castration-resistant prostate cancer through molecular dynamics simulation. J Phys Chem B 129(20):4969\u20134981. https:\/\/doi.org\/10.1021\/acs.jpcb.5c02125","journal-title":"J Phys Chem B"},{"issue":"4","key":"762_CR89","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.3390\/ijms24044154","volume":"24","author":"T Louren\u00e7o","year":"2023","unstructured":"Louren\u00e7o T, Vale N (2023) Pharmacological efficacy of repurposing drugs in the treatment of prostate cancer. Int J Mol Sci 24(4):4154. https:\/\/doi.org\/10.3390\/ijms24044154","journal-title":"Int J Mol Sci"},{"issue":"1","key":"762_CR84","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1021\/acsomega.2c05821","volume":"8","author":"JA Malik","year":"2023","unstructured":"Malik JA, Ahmed S, Momin SS, Shaikh S, Alafnan A, Alanazi J, Said Almermesh MH, Anwar S (2023) Drug repurposing: a new hope in drug discovery for prostate cancer. ACS omega 8(1):56\u201373. https:\/\/doi.org\/10.1021\/acsomega.2c05821","journal-title":"ACS omega"},{"issue":"1","key":"762_CR158","doi-asserted-by":"publisher","first-page":"09","DOI":"10.67316\/jintb.v1.i1.9","volume":"1","author":"BK Mandar","year":"2026","unstructured":"Mandar BK (2026) Artificial intelligence\u2013driven novel drug discovery: target identification to translational impact. J Integr Transl Biomed 1(1):09\u201314. https:\/\/doi.org\/10.67316\/jintb.v1.i1.9","journal-title":"J Integr Transl Biomed"},{"issue":"6","key":"762_CR46","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/ajcp\/aqad182","volume":"161","author":"S Marletta","year":"2024","unstructured":"Marletta S, Eccher A, Martelli FM, Santonicco N, Girolami I, Scarpa A, Pagni F, L\u2019Imperio V, Pantanowitz L, Gobbo S, Seminati D (2024) Artificial intelligence\u2013based algorithms for the diagnosis of prostate cancer: a systematic review. Am J Clin Pathol 161(6):526\u2013534. https:\/\/doi.org\/10.1093\/ajcp\/aqad182","journal-title":"Am J Clin Pathol"},{"issue":"24","key":"762_CR40","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1200\/JCO.22.01856","volume":"41","author":"JM Michalski","year":"2023","unstructured":"Michalski JM, Winter KA, Prestidge BR, Sanda MG, Amin M, Bice WS, Gay HA, Ibbott GS, Crook JM, Catton CN, Raben A (2023) Effect of brachytherapy with external beam radiation therapy versus brachytherapy alone for intermediate-risk prostate cancer: NRG oncology RTOG 0232 randomized clinical trial. J Clin Oncol 41(24):4035\u20134044. https:\/\/doi.org\/10.1200\/JCO.22.01856","journal-title":"J Clin Oncol"},{"issue":"10","key":"762_CR157","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.3390\/genes14101915","volume":"14","author":"M Milano","year":"2023","unstructured":"Milano M, Agapito G, Cannataro M (2023) An exploratory application of multilayer networks and pathway analysis in pharmacogenomics. Genes 14(10):1915. https:\/\/doi.org\/10.3390\/genes14101915","journal-title":"Genes"},{"issue":"24","key":"762_CR121","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.3390\/cells11244121","volume":"11","author":"M Mobashir","year":"2022","unstructured":"Mobashir M, Turunen SP, Izhari MA, Ashankyty IM, Helleday T, Lehti K (2022) An approach for systems-level understanding of prostate cancer from high-throughput data integration to pathway modeling and simulation. Cells 11(24):4121. https:\/\/doi.org\/10.3390\/cells11244121","journal-title":"Cells"},{"key":"762_CR77","doi-asserted-by":"publisher","unstructured":"Momin Y, Beloshe V (2025) Pharmacophore modeling in drug design. In: Advances in Pharmacology, Vol. 103, pp. 313\u2013324. Academic Press. https:\/\/doi.org\/10.1016\/bs.apha.2025.01.010","DOI":"10.1016\/bs.apha.2025.01.010"},{"key":"762_CR35","doi-asserted-by":"publisher","first-page":"877379","DOI":"10.3389\/fonc.2022.877379","volume":"12","author":"F Moreira-Silva","year":"2022","unstructured":"Moreira-Silva F, Henrique R, Jer\u00f3nimo C (2022) From therapy resistance to targeted therapies in prostate cancer. Front Oncol 12:877379. https:\/\/doi.org\/10.3389\/fonc.2022.877379","journal-title":"Front Oncol"},{"issue":"3","key":"762_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.prnil.2024.03.002","volume":"12","author":"S Morizane","year":"2024","unstructured":"Morizane S, Takenaka A (2024) Current status and therapeutic value of extended pelvic lymph node dissection during radical prostatectomy for prostate cancer. Prostate Int 12(3):117\u2013127. https:\/\/doi.org\/10.1016\/j.prnil.2024.03.002","journal-title":"Prostate Int"},{"issue":"12","key":"762_CR45","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.3390\/cancers14122821","volume":"14","author":"\u015eL Moroianu","year":"2022","unstructured":"Moroianu \u015eL, Bhattacharya I, Seetharaman A, Shao W, Kunder CA, Sharma A, Ghanouni P, Fan RE, Sonn GA, Rusu M (2022) Computational detection of extraprostatic extension of prostate cancer on multiparametric MRI using deep learning. Cancers 14(12):2821. https:\/\/doi.org\/10.3390\/cancers14122821","journal-title":"Cancers"},{"issue":"4","key":"762_CR68","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s00894-022-05081-3","volume":"28","author":"S Mukherjee","year":"2022","unstructured":"Mukherjee S, Abdalla M, Yadav M, Madhavi M, Bhrdwaj A, Khandelwal R, Prajapati L, Panicker A, Chaudhary A, Albrakati A, Hussain T (2022) Structure-based virtual screening, molecular docking, and molecular dynamics simulation of VEGF inhibitors for the clinical treatment of ovarian cancer. J Mol Model 28(4):100. https:\/\/doi.org\/10.1007\/s00894-022-05081-3","journal-title":"J Mol Model"},{"issue":"2","key":"762_CR75","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3390\/ddc2020017","volume":"2","author":"TA Oliveira","year":"2023","unstructured":"Oliveira TA, Silva MP, Maia EH, Silva AM, Taranto AG (2023) Virtual screening algorithms in drug discovery: a review focused on machine and deep learning methods. Drugs Drug Candidates 2(2):311\u2013334. https:\/\/doi.org\/10.3390\/ddc2020017","journal-title":"Drugs Drug Candidates"},{"issue":"3","key":"762_CR32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/diagnostics15030288","volume":"15","author":"N Paesano","year":"2025","unstructured":"Paesano N, Picola N, Mu\u00f1oz-Rodriguez J, Ruiz-Plazas X, Mu\u00f1oz-Rivero MV, Celma A, Garc\u00eda-de Manuel G, Mir\u00f3 B, Servian P, Abascal JM, Trilla E (2025) Efficacy of prostate biopsies via transperineal and transrectal routes for significant prostate cancer detection: a multicenter paired\u2013matched study. Diagnostics 15(3):288. https:\/\/doi.org\/10.3390\/diagnostics15030288","journal-title":"Diagnostics"},{"issue":"2","key":"762_CR17","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.1097\/JS9.0000000000003919","volume":"112","author":"W Pan","year":"2026","unstructured":"Pan W, Xing J, Chen X, Xue R, Xu G, Li S, Yi H, Jin B, Wan X, Sang X, Zheng Y (2026) Urinary biomarkers in cancer detection: explorations, advancements, challenges, and future directions. Int J Surg 112(2):4762\u20134788. https:\/\/doi.org\/10.1097\/JS9.0000000000003919","journal-title":"Int J Surg"},{"issue":"20","key":"762_CR82","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2174\/1568026622666220701091339","volume":"22","author":"P Pasrija","year":"2022","unstructured":"Pasrija P, Jha P, Upadhyaya P, Khan MS, Chopra M (2022) Machine learning and artificial intelligence: a paradigm shift in big data-driven drug design and discovery. Curr Top Med Chem 22(20):1692\u20131727. https:\/\/doi.org\/10.2174\/1568026622666220701091339","journal-title":"Curr Top Med Chem"},{"key":"762_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-026-16232-7","author":"CA Pedersen","year":"2026","unstructured":"Pedersen CA, Wess M, Andersen MK, Midtbust E, Sharma A, Fleischer T, Rye MB, Tessem MB (2026) Integrated multi-omics profiling uncovers the epigenetic, transcriptional, and metabolic landscape of prostate cancer progression. BMC Cancer. https:\/\/doi.org\/10.1186\/s12885-026-16232-7","journal-title":"BMC Cancer"},{"issue":"2","key":"762_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/medsci10020025","volume":"10","author":"F Pinto","year":"2022","unstructured":"Pinto F, Dibitetto F, Ragonese M, Bassi P (2022) Mechanisms of resistance to second-generation antiandrogen therapy for prostate cancer: actual knowledge and perspectives. Med Sci 10(2):25. https:\/\/doi.org\/10.3390\/medsci10020025","journal-title":"Med Sci"},{"key":"762_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-026-01035-7","author":"A Ponsiglione","year":"2026","unstructured":"Ponsiglione A, Schoots IG, Padhani AR (2026) The evolving PI-RADS paradigm. Cancer Imaging. https:\/\/doi.org\/10.1186\/s40644-026-01035-7","journal-title":"Cancer Imaging"},{"issue":"2","key":"762_CR24","doi-asserted-by":"publisher","first-page":"e1764","DOI":"10.1002\/cnr2.1764","volume":"6","author":"A Pulumati","year":"2023","unstructured":"Pulumati A, Pulumati A, Dwarakanath BS, Verma A, Papineni RV (2023) Technological advancements in cancer diagnostics: improvements and limitations. Cancer Rep 6(2):e1764. https:\/\/doi.org\/10.1002\/cnr2.1764","journal-title":"Cancer Rep"},{"key":"762_CR85","doi-asserted-by":"publisher","first-page":"108329","DOI":"10.1016\/j.compbiolchem.2024.108329","volume":"115","author":"J Rafiee","year":"2025","unstructured":"Rafiee J, Jamialahmadi K, Bazyari MJ, Aghaee-Bakhtiari SH (2025) Drug repositioning in castration-resistant prostate cancer using systems biology and computational drug design techniques. Comput Biol Chem 115:108329. https:\/\/doi.org\/10.1016\/j.compbiolchem.2024.108329","journal-title":"Comput Biol Chem"},{"issue":"3","key":"762_CR105","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.3390\/ijms24032289","volume":"24","author":"F Raith","year":"2023","unstructured":"Raith F, O\u2019Donovan DH, Lemos C, Politz O, Haendler B (2023) Addressing the reciprocal crosstalk between the AR and the PI3K\/AKT\/mTOR signaling pathways for prostate cancer treatment. Int J Mol Sci 24(3):2289. https:\/\/doi.org\/10.3390\/ijms24032289","journal-title":"Int J Mol Sci"},{"key":"762_CR20","doi-asserted-by":"publisher","DOI":"10.2174\/97898152741341250101","volume-title":"Advanced computing solutions for healthcare","year":"2025","unstructured":"Rajagopal S, Prakasam P, Konguvel E, Subramaniam S, Al Shakarchi AS, Prabadevi B (eds) (2025) Advanced computing solutions for healthcare. Bentham Science, Netherlands. https:\/\/doi.org\/10.2174\/97898152741341250101"},{"issue":"30","key":"762_CR97","doi-asserted-by":"publisher","first-page":"11515","DOI":"10.1021\/acs.nanolett.5c02826","volume":"25","author":"S Rejinold","year":"2025","unstructured":"Rejinold S, Jin GW, Choy JH (2025) A strategic antimetastatic solution for bone-targeting prostate cancer via nanoengineered niclosamide. Nano Lett 25(30):11515. https:\/\/doi.org\/10.1021\/acs.nanolett.5c02826","journal-title":"Nano Lett"},{"issue":"3","key":"762_CR136","doi-asserted-by":"publisher","first-page":"e438516","DOI":"10.1200\/EDBK_438516","volume":"44","author":"IB Riaz","year":"2024","unstructured":"Riaz IB, Harmon S, Chen Z, Naqvi SA, Cheng L (2024) Applications of artificial intelligence in prostate cancer care: a path to enhanced efficiency and outcomes. Am Soc Clin Oncol Educational Book 44(3):e438516. https:\/\/doi.org\/10.1200\/EDBK_438516","journal-title":"Am Soc Clin Oncol Educational Book"},{"issue":"1","key":"762_CR140","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s13721-024-00471-4","volume":"13","author":"K Sailunaz","year":"2024","unstructured":"Sailunaz K, Be\u015ftepe D, Alhajj L, \u00d6zyer T, Rokne J, Alhajj R (2024) A survey of artificial intelligence\/machine learning-based trends for prostate cancer analysis. Netw Model Anal Health Inf Bioinf 13(1):38. https:\/\/doi.org\/10.1007\/s13721-024-00471-4","journal-title":"Netw Model Anal Health Inf Bioinf"},{"issue":"1","key":"762_CR12","doi-asserted-by":"publisher","first-page":"18452","DOI":"10.1038\/s41598-022-21656-9","volume":"12","author":"N Sayyadi","year":"2022","unstructured":"Sayyadi N, Justiniano I, Wang Y, Zheng X, Zhang W, Jiang L, Polikarpov DM, Willows RD, Gillatt D, Campbell D, Walsh BJ (2022) Detection of rare prostate cancer cells in human urine offers prospect of non-invasive diagnosis. Sci Rep 12(1):18452. https:\/\/doi.org\/10.1038\/s41598-022-21656-9","journal-title":"Sci Rep"},{"issue":"3","key":"762_CR5","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","volume":"87","author":"EJ Schafer","year":"2025","unstructured":"Schafer EJ, Laversanne M, Sung H, Soerjomataram I, Briganti A, Dahut W, Bray F, Jemal A (2025) Recent patterns and trends in global prostate cancer incidence and mortality: an update. Eur Urol 87(3):302\u2013313. https:\/\/doi.org\/10.1016\/j.eururo.2024.11.013","journal-title":"Eur Urol"},{"issue":"3","key":"762_CR15","doi-asserted-by":"publisher","first-page":"188904","DOI":"10.1016\/j.bbcan.2023.188904","volume":"1878","author":"SC Selvakumar","year":"2023","unstructured":"Selvakumar SC, Preethi KA, Sekar D (2023) MicroRNAs as important players in regulating cancer through PTEN\/PI3K\/AKT signalling pathways. Biochim Biophys Acta (BBA) Rev Cancer 1878(3):188904. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188904","journal-title":"Biochim Biophys Acta (BBA) Rev Cancer"},{"issue":"5","key":"762_CR74","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1021\/acsmedchemlett.5c00126","volume":"16","author":"Z Shen","year":"2025","unstructured":"Shen Z, Seabra G, Li C (2025) Virtual high-throughput screening of ligands for disrupting PRMT5\/pICLn interaction in prostate cancer cells. ACS Med Chem Lett 16(5):875. https:\/\/doi.org\/10.1021\/acsmedchemlett.5c00126","journal-title":"ACS Med Chem Lett"},{"issue":"9","key":"762_CR111","doi-asserted-by":"publisher","first-page":"844","DOI":"10.3390\/membranes12090844","volume":"12","author":"S Sinha","year":"2022","unstructured":"Sinha S, Tam B, Wang SM (2022) Applications of molecular dynamics simulation in protein study. Membranes 12(9):844. https:\/\/doi.org\/10.3390\/membranes12090844","journal-title":"Membranes"},{"issue":"5","key":"762_CR107","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3390\/cancers17050774","volume":"17","author":"M Siskin","year":"2025","unstructured":"Siskin M, Economides MP, Wise DR (2025) Cyclin-dependent kinase inhibition in prostate cancer: past, present, and future. Cancers 17(5):774. https:\/\/doi.org\/10.3390\/cancers17050774","journal-title":"Cancers"},{"key":"762_CR54","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.euros.2025.03.006","volume":"75","author":"TF Soeterik","year":"2025","unstructured":"Soeterik TF, Wu X, Van den Bergh RC, Kesch C, Zattoni F, Falagario U, Martini A, Miszczyk M, Fasulo V, Maggi M, Kasivisvanathan V (2025) Personalised prostate cancer diagnosis: evaluating biomarker-based approaches to reduce unnecessary magnetic resonance imaging and biopsy procedures. Eur Urol Open Sci 75:106\u2013119. https:\/\/doi.org\/10.1016\/j.euros.2025.03.006","journal-title":"Eur Urol Open Sci"},{"issue":"13","key":"762_CR94","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2174\/1568026623666230130150029","volume":"23","author":"SM Sousa","year":"2023","unstructured":"Sousa SM, Xavier CP, Vasconcelos MH, Palmeira A (2023) Repurposing some of the well-known non-steroid anti-inflammatory drugs (NSAIDs) for cancer treatment. Curr Top Med Chem 23(13):1171\u20131195. https:\/\/doi.org\/10.2174\/1568026623666230130150029","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"762_CR6","doi-asserted-by":"publisher","first-page":"e70043","DOI":"10.3322\/caac.70043","volume":"76","author":"H Sung","year":"2026","unstructured":"Sung H, Jemal A, Siegel R, Kratzer T, Wagle N (2026) Cancer statistics, 2026. Cancer J Clin 76(1):e70043. https:\/\/doi.org\/10.3322\/caac.70043","journal-title":"Cancer J Clin"},{"issue":"1","key":"762_CR95","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/s41598-025-86521-x","volume":"15","author":"S Suzuki","year":"2025","unstructured":"Suzuki S, Negoro H, Kubota M, Sumiyoshi T, Saito R, Okuno T, Segawa T, Fukuzawa S, Onishi H, Hattahara K, Nagahama K (2025) Impact of aspirin on biochemical recurrence of prostate cancer after robot assisted radical prostatectomy in a multicenter retrospective cohort study. Sci Rep 15(1):2025. https:\/\/doi.org\/10.1038\/s41598-025-86521-x","journal-title":"Sci Rep"},{"issue":"23","key":"762_CR14","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.3390\/cells11233776","volume":"11","author":"M Taheri","year":"2022","unstructured":"Taheri M, Safarzadeh A, Hussen BM, Ghafouri-Fard S, Baniahmad A (2022) LncRNA\/miRNA\/mRNA network introduces novel biomarkers in prostate cancer. Cells 11(23):3776. https:\/\/doi.org\/10.3390\/cells11233776","journal-title":"Cells"},{"issue":"9","key":"762_CR101","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1080\/17460441.2021.1883585","volume":"16","author":"Z Tanoli","year":"2021","unstructured":"Tanoli Z, V\u00e4h\u00e4-Koskela M, Aittokallio T (2021) Artificial intelligence, machine learning, and drug repurposing in cancer. Expert Opin Drug Discov 16(9):977\u2013989. https:\/\/doi.org\/10.1080\/17460441.2021.1883585","journal-title":"Expert Opin Drug Discov"},{"issue":"7","key":"762_CR37","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.3390\/cancers14071688","volume":"14","author":"M Terlizzi","year":"2022","unstructured":"Terlizzi M, Limkin EJ, Moukasse Y, Blanchard P (2022) Adjuvant or salvage radiation therapy for prostate cancer after prostatectomy: current status, controversies and perspectives. Cancers 14(7):1688. https:\/\/doi.org\/10.3390\/cancers14071688","journal-title":"Cancers"},{"issue":"1","key":"762_CR138","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s44371-026-00567-y","volume":"3","author":"KR Thombre","year":"2026","unstructured":"Thombre KR, Gabhane V, Gupta KR, Umekar MJ (2026) Network pharmacology in the multi-omics era: uncovering novel therapeutic strategies. Discov Chem 3(1):111. https:\/\/doi.org\/10.1007\/s44371-026-00567-y","journal-title":"Discov Chem"},{"issue":"4","key":"762_CR25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/CU9.0000000000000145","volume":"16","author":"A Tidd-Johnson","year":"2022","unstructured":"Tidd-Johnson A, Sebastian SA, Co EL, Afaq M, Kochhar H, Sheikh M, Mago A, Poudel S, Fernandez JA, Rodriguez ID, Razdan S (2022) Prostate cancer screening: continued controversies and novel biomarker advancements. Curr Urol 16(4):197. https:\/\/doi.org\/10.1097\/CU9.0000000000000145","journal-title":"Curr Urol"},{"key":"762_CR42","doi-asserted-by":"publisher","unstructured":"Tiwari A, Mishra B, Tripathi AS, Mohapatra L, Yasir M, Maurya RK, Prajapati BG Introduction to prostate cancer and conventional therapies. In: Nanocarriers in Prostate Cancer 2026 (pp. 1\u201322). Academic Press. https:\/\/doi.org\/10.1016\/B978-0-443-33208-1.00006-8","DOI":"10.1016\/B978-0-443-33208-1.00006-8"},{"issue":"5","key":"762_CR92","doi-asserted-by":"publisher","first-page":"e2078","DOI":"10.1002\/cnr2.2078","volume":"7","author":"S Tripathi","year":"2024","unstructured":"Tripathi S, Gupta E, Galande S (2024) Statins as anti-tumor agents: a paradigm for repurposed drugs. Cancer Rep 7(5):e2078. https:\/\/doi.org\/10.1002\/cnr2.2078","journal-title":"Cancer Rep"},{"issue":"10","key":"762_CR102","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00210-022-02263-x","volume":"395","author":"KS Turabi","year":"2022","unstructured":"Turabi KS, Deshmukh A, Paul S, Swami D, Siddiqui S, Kumar U, Naikar S, Devarajan S, Basu S, Paul MK, Aich J (2022) Drug repurposing: an emerging strategy in cancer therapeutics. Naunyn Schmiedebergs Arch Pharmacol 395(10):1139\u20131158. https:\/\/doi.org\/10.1007\/s00210-022-02263-x","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"762_CR141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.25163\/ai.1110405","volume":"1","author":"MM Uddin","year":"2025","unstructured":"Uddin MM (2025) Machine learning in cancer biology: transforming diagnosis, prognosis, and treatment in modern medical research. J Ai ML DL 1(1):1\u20130. https:\/\/doi.org\/10.25163\/ai.1110405","journal-title":"J Ai ML DL"},{"key":"762_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.4397","author":"JM Unger","year":"2024","unstructured":"Unger JM, Till C, Tangen CM, Hershman DL, Goodman PJ, LeBlanc M, Barlow WE, Vaidya R, Minasian LM, Parnes HL, Thompson IM Jr (2024) Long-term adverse effects and complications after prostate cancer treatment. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2024.4397","journal-title":"JAMA Oncol"},{"issue":"2","key":"762_CR80","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2174\/1570180819666220420092723","volume":"20","author":"J Venkatesan","year":"2023","unstructured":"Venkatesan J, Thangavelu P, Jubie S, Jayapalan S, Sivakumar T (2023) A machine learning language to build a QSAR model of pyrazoline derivative inhibitors targeting Mycobacterium tuberculosis strain H37Rv. Lett Drug Des Discovery 20(2):167\u2013180. https:\/\/doi.org\/10.2174\/1570180819666220420092723","journal-title":"Lett Drug Des Discovery"},{"issue":"12","key":"762_CR58","doi-asserted-by":"publisher","first-page":"e43533","DOI":"10.1016\/j.heliyon.2025.e43533","volume":"11","author":"M Villa","year":"2025","unstructured":"Villa M, Cazzaniga G, Bolognesi M, Malighetti F, Crippa V, Aroldi A, Bozzini G, Pagni F, Piazza R, Mologni L, Ramazzotti D (2025) Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers. Heliyon 11(12):e43533. https:\/\/doi.org\/10.1016\/j.heliyon.2025.e43533","journal-title":"Heliyon"},{"key":"762_CR59","doi-asserted-by":"publisher","first-page":"189426","DOI":"10.1016\/j.bbcan.2025.189426","volume":"1880","author":"Y Wang","year":"2025","unstructured":"Wang Y, Wang F, Pan Q, Wang J (2025) Integrating multi-omics proteomic approaches in deciphering the tumor microenvironment and therapeutic resistance mechanisms in prostate cancer. Biochim Biophys Acta (BBA) Rev Cancer 1880:189426. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189426","journal-title":"Biochim Biophys Acta (BBA) Rev Cancer"},{"issue":"1","key":"762_CR154","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41746-025-01930-6","volume":"8","author":"Y Wang","year":"2025","unstructured":"Wang Y, Zhu H, Ren J, Ren M (2025) Integrative machine learning models predict prostate cancer diagnosis and biochemical recurrence risk: advancing precision oncology. NPJ Digit Med 8(1):524. https:\/\/doi.org\/10.1038\/s41746-025-01930-6","journal-title":"NPJ Digit Med"},{"key":"762_CR61","doi-asserted-by":"publisher","first-page":"893424","DOI":"10.3389\/fonc.2022.893424","volume":"12","author":"Z Wei","year":"2022","unstructured":"Wei Z, Han D, Zhang C, Wang S, Liu J, Chao F, Song Z, Chen G (2022) Deep learning-based multi-omics integration robustly predicts relapse in prostate cancer. Front Oncol 12:893424. https:\/\/doi.org\/10.3389\/fonc.2022.893424","journal-title":"Front Oncol"},{"key":"762_CR151","doi-asserted-by":"publisher","first-page":"893424","DOI":"10.3389\/fonc.2022.893424","volume":"12","author":"Z Wei","year":"2022","unstructured":"Wei Z, Han D, Zhang C, Wang S, Liu J, Chao F, Song Z, Chen G (2022) Deep learning-based multi-omics integration robustly predicts relapse in prostate cancer. Front Oncol 12:893424. https:\/\/doi.org\/10.3389\/fonc.2022.893424","journal-title":"Front Oncol"},{"issue":"1150","key":"762_CR142","doi-asserted-by":"publisher","first-page":"20230211","DOI":"10.1259\/bjr.20230211","volume":"96","author":"L Wei","year":"2023","unstructured":"Wei L, Niraula D, Gates ED, Fu J, Luo Y, Nyflot MJ, Bowen SR, El Naqa IM, Cui S (2023) Artificial intelligence (AI) and machine learning (ML) in precision oncology: a review on enhancing discoverability through multiomics integration. Br J Radiol 96(1150):20230211. https:\/\/doi.org\/10.1259\/bjr.20230211","journal-title":"Br J Radiol"},{"key":"762_CR119","doi-asserted-by":"publisher","first-page":"791269","DOI":"10.3389\/fphar.2021.791269","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu Y, You X, Lin Q, Xiong W, Guo Y, Huang Z, Dai X, Chen Z, Mei S, Long Y, Tian X (2022) Exploring the pharmacological mechanisms of Xihuang Pills against prostate cancer via integrating network pharmacology and experimental validation in vitro and in vivo. Front Pharmacol 12:791269. https:\/\/doi.org\/10.3389\/fphar.2021.791269","journal-title":"Front Pharmacol"},{"issue":"12","key":"762_CR118","doi-asserted-by":"publisher","first-page":"100016","DOI":"10.1016\/j.cjnm.2025.100016","volume":"23","author":"Z Xiao","year":"2025","unstructured":"Xiao Z, Jiang S, Fu S, Zhang X, Qi X, Li C (2025) Unveiling the therapeutic mechanism of Epimedium Herba on prostate cancer through network pharmacology and experimental validation. Chin J Nat Med 23(12):100016. https:\/\/doi.org\/10.1016\/j.cjnm.2025.100016","journal-title":"Chin J Nat Med"},{"issue":"2","key":"762_CR127","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.3390\/ijms24021270","volume":"24","author":"S Xu","year":"2023","unstructured":"Xu S, Kondal MD, Ahmad A, Zhu R, Fan L, Zaborniak P, Madden KS, de Souza JV, Bronowska AK (2023) Mechanistic investigation of the androgen receptor DNA-binding domain and modulation via direct interactions with DNA abasic sites: understanding the mechanisms involved in castration-resistant prostate cancer. Int J Mol Sci 24(2):1270. https:\/\/doi.org\/10.3390\/ijms24021270","journal-title":"Int J Mol Sci"},{"issue":"8","key":"762_CR114","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.4314\/tjpr.v21i8.14","volume":"21","author":"S Xun","year":"2022","unstructured":"Xun S, Jiao M, Li J, Zhang X, Zhang A, He H, Zou J, Duan C, Zhang X (2022) Network pharmacology and GEO chip-based elucidation of mechanisms underlying the use of Yi Tieqing for prevention and treatment of postoperative nausea and vomiting. Trop J Pharm Res 21(8):1675. https:\/\/doi.org\/10.4314\/tjpr.v21i8.14","journal-title":"Trop J Pharm Res"},{"issue":"1","key":"762_CR98","doi-asserted-by":"publisher","first-page":"110","DOI":"10.21608\/aps.2024.332916.1207","volume":"9","author":"MN Yassa","year":"2025","unstructured":"Yassa MN, Mansour M, ElKhateeb DG, Awad GA (2025) Repurposing strategies and benefits in light of itraconazole interrelated therapeutic activities and challenges. Archives Pharm Sci Ain Shams Univ 9(1):110\u2013119. https:\/\/doi.org\/10.21608\/aps.2024.332916.1207","journal-title":"Archives Pharm Sci Ain Shams Univ"},{"issue":"1","key":"762_CR91","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41392-023-01516-2","volume":"8","author":"J Ye","year":"2023","unstructured":"Ye J, Cai S, Feng Y, Li J, Cai Z, Deng Y, Liu R, Zhu X, Lu J, Zhuo Y, Liang Y (2023) Metformin escape in prostate cancer by activating the PTGR1 transcriptional program through a novel super-enhancer. Signal Transduct Target Therapy 8(1):303. https:\/\/doi.org\/10.1038\/s41392-023-01516-2","journal-title":"Signal Transduct Target Therapy"},{"issue":"6","key":"762_CR149","doi-asserted-by":"publisher","first-page":"030006052110143","DOI":"10.1177\/03000605211014301","volume":"49","author":"N Yu","year":"2021","unstructured":"Yu N, Wang B, Ren J, Wu H, Gao Y, Liu A, Niu G (2021) The clinical guiding value of a radiomics model for androgen deprivation therapy for prostate cancer. J Int Med Res 49(6):03000605211014301. https:\/\/doi.org\/10.1177\/03000605211014301","journal-title":"J Int Med Res"},{"issue":"7","key":"762_CR19","doi-asserted-by":"publisher","first-page":"6729","DOI":"10.1021\/acsomega.2c07346","volume":"8","author":"T Yu","year":"2023","unstructured":"Yu T, Nantasenamat C, Kachenton S, Anuwongcharoen N, Piacham T (2023) Cheminformatic analysis and machine learning modeling to investigate androgen receptor antagonists to combat prostate cancer. ACS omega 8(7):6729. https:\/\/doi.org\/10.1021\/acsomega.2c07346","journal-title":"ACS omega"},{"issue":"2","key":"762_CR27","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3390\/ijms26020704","volume":"26","author":"M \u017dvirbl\u0117","year":"2025","unstructured":"\u017dvirbl\u0117 M, Vaicekauskait\u0117 I, Survila \u017d, Bosas P, Dobrovolskien\u0117 N, Mlynska A, Sabaliauskait\u0117 R, Pa\u0161ukonien\u0117 V (2025) Liquid-based diagnostic panels for prostate cancer: the synergistic role of soluble PD-L1, PD-1, and mRNA biomarkers. Int J Mol Sci 26(2):704. https:\/\/doi.org\/10.3390\/ijms26020704","journal-title":"Int J Mol Sci"},{"issue":"2","key":"762_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.14744\/ijmb.2024.93585","volume":"7","author":"S Zakari","year":"2024","unstructured":"Zakari S, Ekenwaneze CC, Amadi EC, AbuHamdia A, Ogunlana OO (2024) Unveiling the latest insights into Androgen Receptors in Prostate Cancer. Int J Med Biochem 7(2):101. https:\/\/doi.org\/10.14744\/ijmb.2024.93585","journal-title":"Int J Med Biochem"},{"issue":"1","key":"762_CR113","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13020-024-01056-z","volume":"20","author":"Y Zhai","year":"2025","unstructured":"Zhai Y, Liu L, Zhang F, Chen X, Wang H, Zhou J, Chai K, Liu J, Lei H, Lu P, Guo M (2025) Network pharmacology: a crucial approach in traditional Chinese medicine research. Chin Med 20(1):8. https:\/\/doi.org\/10.1186\/s13020-024-01056-z","journal-title":"Chin Med"},{"issue":"1","key":"762_CR115","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12906-024-04572-5","volume":"24","author":"X Zhan","year":"2024","unstructured":"Zhan X, Li H, Jin J, Ju X, Gao J, Chen X, Yuan F, Gu J, Xu D, Ju G (2024) Network pharmacology and experimental validation to explore the role and potential mechanism of Liuwei Dihuang Decoction in prostate cancer. BMC Complement Med Ther 24(1):284. https:\/\/doi.org\/10.1186\/s12906-024-04572-5","journal-title":"BMC Complement Med Ther"},{"issue":"7","key":"762_CR64","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1080\/17460441.2024.2365370","volume":"19","author":"W Zhang","year":"2024","unstructured":"Zhang W, Huang RS (2024) Computer-aided drug discovery strategies for novel therapeutics for prostate cancer leveraging next-generation sequencing data. Expert Opin Drug Discov 19(7):841\u2013853. https:\/\/doi.org\/10.1080\/17460441.2024.2365370","journal-title":"Expert Opin Drug Discov"},{"issue":"7","key":"762_CR139","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12032-025-02811-4","volume":"42","author":"Z Zhao","year":"2025","unstructured":"Zhao Z, Le J, Fu Z, Yang S, Chen Y (2025) Cancer network pharmacology: multi-network regulatory mechanisms and future directions. Med Oncol 42(7):255. https:\/\/doi.org\/10.1007\/s12032-025-02811-4","journal-title":"Med Oncol"},{"issue":"19","key":"762_CR124","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.3390\/cancers14194877","volume":"14","author":"Z Zheng","year":"2022","unstructured":"Zheng Z, Li J, Liu Y, Shi Z, Xuan Z, Yang K, Xu C, Bai Y, Fu M, Xiao Q, Sun H (2022) The crucial role of AR-V7 in enzalutamide-resistance of castration-resistant prostate cancer. Cancers 14(19):4877. https:\/\/doi.org\/10.3390\/cancers14194877","journal-title":"Cancers"},{"issue":"1","key":"762_CR72","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1021\/acs.jmedchem.3c00996","volume":"67","author":"H Zhong","year":"2023","unstructured":"Zhong H, Wang X, Chen S, Wang Z, Wang H, Xu L, Hou T, Yao X, Li D, Pan P (2023) Discovery of novel inhibitors of BRD4 for treating prostate cancer: a comprehensive case study for considering water networks in virtual screening and drug design. J Med Chem 67(1):138\u2013151. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00996","journal-title":"J Med Chem"},{"issue":"13","key":"762_CR50","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.3390\/diagnostics13132283","volume":"13","author":"M Zhu","year":"2023","unstructured":"Zhu M, Liang Z, Feng T, Mai Z, Jin S, Wu L, Zhou H, Chen Y, Yan W (2023) Up-to-date imaging and diagnostic techniques for prostate cancer: a literature review. Diagnostics 13(13):2283. https:\/\/doi.org\/10.3390\/diagnostics13132283","journal-title":"Diagnostics"},{"issue":"4","key":"762_CR156","doi-asserted-by":"publisher","first-page":"200","DOI":"10.62347\/JSAE9732","volume":"12","author":"M Zhu","year":"2024","unstructured":"Zhu M, Sali R, Baba F, Khasawneh H, Ryndin M, Leveillee RJ, Hurwitz MD, Lui K, Dixon C, Zhang DY (2024) Artificial intelligence in pathologic diagnosis, prognosis and prediction of prostate cancer. Am J Clin Experimental Urol 12(4):200. https:\/\/doi.org\/10.62347\/JSAE9732","journal-title":"Am J Clin Experimental Urol"},{"key":"762_CR120","doi-asserted-by":"publisher","first-page":"1530715","DOI":"10.3389\/fphar.2025.1530715","volume":"16","author":"G Zhu","year":"2025","unstructured":"Zhu G, Jiang Z, Zhu N, Wang D, Guo T, Meng Y, Zhu Y, Tan K, Hu M, Tang H, Wang X (2025) Exploring the multi-targeted mechanism of Saikosaponin A in prostate cancer treatment: a network pharmacology and molecular docking approach. Front Pharmacol 16:1530715. https:\/\/doi.org\/10.3389\/fphar.2025.1530715","journal-title":"Front Pharmacol"},{"issue":"1","key":"762_CR99","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/medsci14010055","volume":"14","author":"CE Zonfa","year":"2026","unstructured":"Zonfa CE, Thyagarajan A, Sahu RP (2026) Repurposing itraconazole in combination with chemotherapy and immune checkpoint inhibitor for cancer. Med Sci 14(1):55. https:\/\/doi.org\/10.3390\/medsci14010055","journal-title":"Med Sci"}],"container-title":["In Silico Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40203-026-00762-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40203-026-00762-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40203-026-00762-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:45:23Z","timestamp":1791096323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40203-026-00762-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,4]]},"references-count":158,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["762"],"URL":"https:\/\/doi.org\/10.1007\/s40203-026-00762-w","relation":{},"ISSN":["2193-9616"],"issn-type":[{"value":"2193-9616","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,4]]},"assertion":[{"value":"7 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"254"}}